KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $17.1 million.

  • Xenon Pharmaceuticals' Prepaid Assets rose 26399.91% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 26399.91%. This contributed to the annual value of $6.9 million for FY2024, which is 1471.86% up from last year.
  • Xenon Pharmaceuticals' Prepaid Assets amounted to $17.1 million in Q3 2025, which was up 26399.91% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Prepaid Assets registered a high of $17.1 million during Q3 2025, and its lowest value of $2.9 million during Q2 2023.
  • Moreover, its 5-year median value for Prepaid Assets was $4.8 million (2022), whereas its average is $6.1 million.
  • In the last 5 years, Xenon Pharmaceuticals' Prepaid Assets skyrocketed by 299469.03% in 2021 and then plummeted by 5852.63% in 2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Prepaid Assets (Quarter) stood at $4.5 million in 2021, then soared by 61.24% to $7.2 million in 2022, then fell by 16.87% to $6.0 million in 2023, then grew by 14.72% to $6.9 million in 2024, then soared by 147.56% to $17.1 million in 2025.
  • Its Prepaid Assets stands at $17.1 million for Q3 2025, versus $11.6 million for Q2 2025 and $7.3 million for Q1 2025.